The Business of Biofabrication

Swiss TechBio company CUTISS has closed a CHF 56 million (≈USD 62 million) Series C financing round, bringing its total funds raised to over CHF 125 million. The new capital will support the ongoing Phase 3 trials of its personalized, bio-engineered skin graft denovoSkin™, and prepare for commercial launch.

The round was co-led by the family office of Giammaria Giuliani and a U.S. family represented by Shiloh Advisors, with participation from new investors including Swisspreneur. CUTISS also signed a strategic agreement with the Rode Kruis Ziekenhuis (RKZ) burn center in the Netherlands, laying the groundwork for the company’s first international production site once denovoSkin™ receives regulatory approval.

denovoSkin™, a bilayer autologous skin graft designed for burn and reconstructive surgery, is currently enrolling adolescent and adult patients across eight EU countries. Early data show the graft matures quickly, integrates with minimal scarring, and grows with the patient, potentially reducing the need for additional skin harvesting and follow-up surgeries. First Phase 3 data are expected by late 2026.

Beyond its lead product, CUTISS is scaling a fully automated manufacturing platform to enable cost-effective, decentralized production of personalized tissue therapies. The company is also preparing the European launch of VitiCell®, a CE-marked device for cell-based treatment of skin-pigmentation disorders.

This funding milestone underscores investor confidence in CUTISS’s push to industrialize personalized skin-tissue engineering and expand regenerative medicine manufacturing capacity in Europe and beyond.

Founded in 2017 as a spin-off from the University of Zurich’s Tissue Biology Research Unit, CUTISS AG develops personalized tissue-engineered therapies to transform skin surgery and regenerative medicine. Its flagship product, denovoSkin™, is a living, autologous skin graft designed to reduce donor-site harvesting and improve functional and aesthetic outcomes for patients with severe burns or other skin injuries. CUTISS is also pioneering the world’s first fully automated platform for large-scale production of customized human skin tissue and holds exclusive rights to VitiCell®, a device for autologous cell grafting in vitiligo and other pigmentation disorders. Learn more at www.cutiss.com.